Can Fite Biopharma’s (CANF) “Buy” Rating Reaffirmed at Roth Capital
Can Fite Biopharma Ltd (AMEX:CANF)‘s stock had its “buy” rating restated by stock analysts at Roth Capital in a report released on Wednesday, StockTargetPrices.com reports.
Separately, Rodman & Renshaw initiated coverage on Can Fite Biopharma in a report on Monday, August 29th. They issued a “buy” rating and a $6.00 target price for the company.
Shares of Can Fite Biopharma (AMEX:CANF) traded down 0.41% during midday trading on Wednesday, hitting $2.44. The stock had a trading volume of 68,715 shares. Can Fite Biopharma has a 52 week low of $1.85 and a 52 week high of $4.05. The stock has a 50 day moving average price of $2.50 and a 200-day moving average price of $2.56. The stock’s market capitalization is $34.71 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/can-fite-biopharmas-canf-buy-rating-reaffirmed-at-roth-capital.html
About Can Fite Biopharma
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.